|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGF2 |
Gene summary for IGF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGF2 | Gene ID | 3481 |
| Gene name | insulin like growth factor 2 | |
| Gene Alias | C11orf43 | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01344 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3481 | IGF2 | AEH-subject1 | Human | Endometrium | AEH | 1.02e-48 | -8.01e-01 | -0.3059 |
| 3481 | IGF2 | AEH-subject2 | Human | Endometrium | AEH | 1.16e-48 | -8.12e-01 | -0.2525 |
| 3481 | IGF2 | AEH-subject3 | Human | Endometrium | AEH | 9.30e-53 | -8.12e-01 | -0.2576 |
| 3481 | IGF2 | AEH-subject4 | Human | Endometrium | AEH | 2.00e-35 | -8.06e-01 | -0.2657 |
| 3481 | IGF2 | AEH-subject5 | Human | Endometrium | AEH | 9.30e-53 | -8.12e-01 | -0.2953 |
| 3481 | IGF2 | EEC-subject1 | Human | Endometrium | EEC | 7.22e-51 | -8.10e-01 | -0.2682 |
| 3481 | IGF2 | EEC-subject2 | Human | Endometrium | EEC | 2.12e-50 | -8.12e-01 | -0.2607 |
| 3481 | IGF2 | EEC-subject3 | Human | Endometrium | EEC | 3.04e-51 | -8.06e-01 | -0.2525 |
| 3481 | IGF2 | EEC-subject4 | Human | Endometrium | EEC | 2.12e-50 | -8.07e-01 | -0.2571 |
| 3481 | IGF2 | EEC-subject5 | Human | Endometrium | EEC | 6.20e-50 | -8.12e-01 | -0.249 |
| 3481 | IGF2 | GSM5276934 | Human | Endometrium | EEC | 2.45e-51 | -8.12e-01 | -0.0913 |
| 3481 | IGF2 | GSM5276935 | Human | Endometrium | EEC | 3.66e-55 | -8.12e-01 | -0.123 |
| 3481 | IGF2 | GSM5276937 | Human | Endometrium | EEC | 5.68e-46 | -8.12e-01 | -0.0897 |
| 3481 | IGF2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.07e-40 | -8.12e-01 | -0.1869 |
| 3481 | IGF2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.42e-33 | -7.96e-01 | -0.1875 |
| 3481 | IGF2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.38e-39 | -7.91e-01 | -0.1883 |
| 3481 | IGF2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.98e-48 | -7.53e-01 | -0.1934 |
| 3481 | IGF2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.50e-46 | -7.85e-01 | -0.1917 |
| 3481 | IGF2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.11e-47 | -7.96e-01 | -0.1916 |
| 3481 | IGF2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.81e-49 | -8.12e-01 | -0.1269 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002240714 | Endometrium | AEH | regulation of cell-cell adhesion | 79/2100 | 448/18723 | 2.90e-05 | 5.40e-04 | 79 |
| GO:00512369 | Endometrium | AEH | establishment of RNA localization | 37/2100 | 166/18723 | 3.13e-05 | 5.66e-04 | 37 |
| GO:00068988 | Endometrium | AEH | receptor-mediated endocytosis | 49/2100 | 244/18723 | 3.54e-05 | 6.24e-04 | 49 |
| GO:00506795 | Endometrium | AEH | positive regulation of epithelial cell proliferation | 43/2100 | 207/18723 | 4.55e-05 | 7.61e-04 | 43 |
| GO:00606697 | Endometrium | AEH | embryonic placenta morphogenesis | 11/2100 | 26/18723 | 5.33e-05 | 8.49e-04 | 11 |
| GO:002240910 | Endometrium | AEH | positive regulation of cell-cell adhesion | 54/2100 | 284/18723 | 6.94e-05 | 1.07e-03 | 54 |
| GO:00310997 | Endometrium | AEH | regeneration | 41/2100 | 198/18723 | 7.29e-05 | 1.11e-03 | 41 |
| GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
| GO:00426925 | Endometrium | AEH | muscle cell differentiation | 68/2100 | 384/18723 | 8.88e-05 | 1.30e-03 | 68 |
| GO:19016539 | Endometrium | AEH | cellular response to peptide | 64/2100 | 359/18723 | 1.16e-04 | 1.63e-03 | 64 |
| GO:00159319 | Endometrium | AEH | nucleobase-containing compound transport | 44/2100 | 222/18723 | 1.19e-04 | 1.66e-03 | 44 |
| GO:00518974 | Endometrium | AEH | positive regulation of protein kinase B signaling | 28/2100 | 120/18723 | 1.20e-04 | 1.67e-03 | 28 |
| GO:19030398 | Endometrium | AEH | positive regulation of leukocyte cell-cell adhesion | 46/2100 | 239/18723 | 1.72e-04 | 2.24e-03 | 46 |
| GO:00421109 | Endometrium | AEH | T cell activation | 81/2100 | 487/18723 | 1.78e-04 | 2.30e-03 | 81 |
| GO:003367414 | Endometrium | AEH | positive regulation of kinase activity | 78/2100 | 467/18723 | 2.03e-04 | 2.54e-03 | 78 |
| GO:00447945 | Endometrium | AEH | positive regulation by host of viral process | 7/2100 | 13/18723 | 2.05e-04 | 2.54e-03 | 7 |
| GO:00018929 | Endometrium | AEH | embryonic placenta development | 21/2100 | 82/18723 | 2.10e-04 | 2.59e-03 | 21 |
| GO:00447885 | Endometrium | AEH | modulation by host of viral process | 11/2100 | 30/18723 | 2.46e-04 | 2.93e-03 | 11 |
| GO:00457877 | Endometrium | AEH | positive regulation of cell cycle | 56/2100 | 313/18723 | 2.73e-04 | 3.14e-03 | 56 |
| GO:004343410 | Endometrium | AEH | response to peptide hormone | 70/2100 | 414/18723 | 2.93e-04 | 3.35e-03 | 70 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
| hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
| hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
| hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
| hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
| hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0520510 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
| hsa0520511 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa0520531 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | CRC | MSS |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | CRC | MSS |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | CRC | MSS |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | Endometrium | Healthy |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | Endometrium | Healthy |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | Endometrium | Healthy |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | Esophagus | ESCC |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | Esophagus | ESCC |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | Esophagus | ESCC |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | HNSCC | ADJ |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | HNSCC | ADJ |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | HNSCC | Healthy |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | HNSCC | OSCC |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | HNSCC | OSCC |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | HNSCC | OSCC |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | HNSCC | Precancer |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | HNSCC | Precancer |
| IGF2 | ITGA6_ITGB4 | IGF2_ITGA6_ITGB4 | IGF | HNSCC | Precancer |
| IGF2 | IGF1R | IGF2_IGF1R | IGF | Liver | Healthy |
| IGF2 | IGF2R | IGF2_IGF2R | IGF | Liver | Healthy |
| Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGF2 | SNV | Missense_Mutation | c.113G>A | p.Gly38Asp | p.G38D | P01344 | protein_coding | deleterious_low_confidence(0.01) | benign(0.099) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| IGF2 | insertion | Frame_Shift_Ins | rs755455183 | c.686_687insC | p.Glu230ArgfsTer50 | p.E230Rfs*50 | P01344 | protein_coding | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IGF2 | SNV | Missense_Mutation | c.311N>A | p.Arg104His | p.R104H | P01344 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| IGF2 | SNV | Missense_Mutation | novel | c.101N>G | p.Ile34Arg | p.I34R | P01344 | protein_coding | deleterious_low_confidence(0) | benign(0.014) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| IGF2 | SNV | Missense_Mutation | rs762200142 | c.358C>T | p.Arg120Cys | p.R120C | P01344 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| IGF2 | SNV | Missense_Mutation | rs369122420 | c.473N>T | p.Pro158Leu | p.P158L | P01344 | protein_coding | deleterious(0) | benign(0.176) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IGF2 | SNV | Missense_Mutation | c.124N>A | p.Glu42Lys | p.E42K | P01344 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-F4-6704-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
| IGF2 | SNV | Missense_Mutation | c.248N>A | p.Arg83His | p.R83H | P01344 | protein_coding | deleterious(0.03) | benign(0.019) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | |
| IGF2 | insertion | Frame_Shift_Ins | rs755455183 | c.686_687insC | p.Glu230ArgfsTer50 | p.E230Rfs*50 | P01344 | protein_coding | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| IGF2 | insertion | Frame_Shift_Ins | rs755455183 | c.686dupC | p.Glu230ArgfsTer50 | p.E230Rfs*50 | P01344 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | Xentuzumab | XENTUZUMAB | ||
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | ANASTROZOLE | ANASTROZOLE | 11983488 | |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | GEFITINIB | GEFITINIB | 16988945 | |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | ANDROGENS | 2229290 | ||
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | GANITUMAB | GANITUMAB | 23741071,24727326 | |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | ETOPOSIDE | ETOPOSIDE | 15019164 | |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | Platinum compounds | 30672383 | ||
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | HGF | 9348194 | ||
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | SOMATOTROPIN | HUMAN GROWTH HORMONE | 9834461 | |
| 3481 | IGF2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, HORMONE ACTIVITY, GROWTH FACTOR, DRUGGABLE GENOME | IFN | 15342387 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |